相似文献
1
Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.
Breast Cancer Res. 2011 Mar 14;13(2):205. doi: 10.1186/bcr2818.
2
Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.
Oncology (Williston Park). 2008 Nov 15;22(12):1401-8.
3
Aromatase inhibitor-associated arthralgia syndrome.
Breast. 2007 Jun;16(3):223-34. doi: 10.1016/j.breast.2007.01.011. Epub 2007 Mar 21.
4
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
Ned Tijdschr Geneeskd. 2006 Dec 30;150(52):2863-9.
5
[Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].
Klin Onkol. 2016 Fall;29 Suppl 3:S39-49. doi: 10.14735/amko20163S39.
6
Aromatase inhibitors and arthralgia: a growing pain?
Oncology (Williston Park). 2008 Nov 15;22(12):1424, 1426.
7
Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Curr Med Res Opin. 2006 Aug;22(8):1609-21. doi: 10.1185/030079906X115667.
8
Toxicity of aromatase inhibitors.
Semin Oncol. 2006 Dec;33(6):688-95. doi: 10.1053/j.seminoncol.2006.08.011.
9
Improving tolerance of AIs: predicting risk and uncovering mechanisms of musculoskeletal toxicity.
Oncology (Williston Park). 2008 Nov 15;22(12):1416, 1424.
10
The effects of adjuvant endocrine therapy on bone health in women with breast cancer.
J Endocrinol. 2019 Jun 1;241(3):R111-R124. doi: 10.1530/JOE-19-0077.
引用本文的文献
1
Aromatase Inhibitor-Induced Carpal Tunnel Syndrome Immunohistochemical Analysis and Clinical Evaluation: An Observational, Cross-Sectional, Case-Control Study.
J Clin Med. 2025 Aug 5;14(15):5513. doi: 10.3390/jcm14155513.
2
Pilot Study of Cannabidiol for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Breast Cancer.
Cancer Med. 2025 Aug;14(15):e71117. doi: 10.1002/cam4.71117.
3
Expanding Horizons of Buprenorphine: A Comprehensive Narrative Review of Its Pharmacological Properties and Clinical Applications in Chronic Pain.
Pain Ther. 2025 Jun 22. doi: 10.1007/s40122-025-00753-3.
4
Deciphering the anti-neoplastic potential of Allium ascalonicum in averting the proliferation and epithelial-mesenchymal transition of triple-negative breast cancer through virtual docking and In Vitro approaches.
BMC Cancer. 2025 Mar 7;25(1):414. doi: 10.1186/s12885-025-13796-8.
5
Risk factors for and incidence of osteoporosis in patients with breast cancer by gender : a nationwide cohort study.
Sci Rep. 2025 Feb 5;15(1):4413. doi: 10.1038/s41598-025-89059-0.
6
Efficacy of a single 5 mg zoledronic acid infusion in preventing bone loss and fracture in postmenopausal women with breast cancer.
J Bone Miner Metab. 2024 Nov;42(6):720-727. doi: 10.1007/s00774-024-01552-0. Epub 2024 Sep 30.
7
The role of exercise in aromatase inhibitor-induced arthralgia.
PM R. 2024 Dec;16(12):1406-1416. doi: 10.1002/pmrj.13193. Epub 2024 May 23.
8
Pain associated with breast cancer: etiologies and therapies.
Front Pain Res (Lausanne). 2023 Dec 11;4:1182488. doi: 10.3389/fpain.2023.1182488. eCollection 2023.
9
Total Hip Arthroplasty With Prophylactic Fixation of Greater Trochanter and Distal Femur in a Patient With a History of Multiple Myeloma and Breast Cancer.
Cureus. 2023 Apr 22;15(4):e37971. doi: 10.7759/cureus.37971. eCollection 2023 Apr.
10
Kinin B and B Receptors Activation Sensitize the TRPA1 Channel Contributing to Anastrozole-Induced Pain Symptoms.
Pharmaceutics. 2023 Apr 3;15(4):1136. doi: 10.3390/pharmaceutics15041136.
本文引用的文献
1
Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study.
Breast Cancer Res Treat. 2011 Feb;125(3):869-78. doi: 10.1007/s10549-010-1075-9. Epub 2010 Jul 28.
2
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.
J Clin Oncol. 2010 Aug 10;28(23):3784-96. doi: 10.1200/JCO.2009.26.3756. Epub 2010 Jul 12.
3
Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women.
J Clin Endocrinol Metab. 2010 Nov;95(11):5063-8. doi: 10.1210/jc.2010-1103. Epub 2010 Jul 7.
4
Cancer statistics, 2010.
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
5
Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.
Br J Cancer. 2010 Jul 27;103(3):291-6. doi: 10.1038/sj.bjc.6605768. Epub 2010 Jul 6.
6
A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography.
Cancer. 2010 Sep 15;116(18):4360-7. doi: 10.1002/cncr.25385.
7
Menopausal arthralgia: Fact or fiction.
Maturitas. 2010 Sep;67(1):29-33. doi: 10.1016/j.maturitas.2010.04.009.
8
Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
Eur J Cancer. 2010 Aug;46(12):2187-95. doi: 10.1016/j.ejca.2010.04.012. Epub 2010 May 13.
9
Regulation of adult bone turnover by sex steroids.
J Cell Physiol. 2010 Aug;224(2):305-10. doi: 10.1002/jcp.22159.
10
New views on treatment of aromatase inhibitors induced arthralgia.
Breast. 2010 Jun;19(3):249-50. doi: 10.1016/j.breast.2010.03.031. Epub 2010 Apr 24.
Zotero 插件